The intracellular second messenger cyclic adenosine monophosphate (cAMP) is pivotal in
the signalling pathways of a number of hormones and agonists which act on cell-surface …

Genetic variation in the ADRB2 gene has been hypothesized to have a role in differential
response to beta-agonist (BA) therapy in asthma. However, study results have been …

Aspirin-intolerant asthma (AIA) is a subtype of bronchial asthma characterized by
development of bronchoconstriction evoked by non-steroidal anti-inflammatory drugs …

Several topics on childhood asthma were addressed in the Paediatric Clinical Year in
Review session at the 2015 European Respiratory Society International Congress. With …

Introduction: Genetic mutations in the β2 receptor could alter its functioning and the
response to β2 agonists. The study was done to find out the effect of two commonly …

BACKGROUND: The role of beta2-agonist is still important to control bronchoconstriction in
asthma. Polymorphisms at aminoacid positions 16 and 27 of the beta2-adrenoceptor gene …

Asthma is a heterogeneous chronic inflammatory disease of the airways, which insufficient
treatment reduces the quality of patient's life. The effectiveness of asthma treatment, the …

Objective: There is conflicting clinical evidence describing the response to long-acting beta-
agonist (LABA) bronchodilators for patients with Arg16Gly β2-adrenergic receptor (ADRB2) …

Phosphodiesterase 4 (PDE 4) enzymes are the principal phosphodiesterases responsible
for the hydrolysis of cAMP in pro-inflammatory leukocytes. The functional consequences of …

Inhibitors of phosphodiesterase-4 (PDE4) are efficacious for allergic asthma in animal
models and have shown some efficacy in human asthma. Regulation of PDE4 in allergy and …